TY - JOUR T1 - Dyspnoea and Symptom Burden in Mild-Moderate COPD: the Canadian Cohort Obstructive Lung Disease Study JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00960-2020 SP - 00960-2020 AU - Mathew Cherian AU - Dennis Jensen AU - Wan C. Tan AU - Sara Mursleen AU - Emma C. Goodall AU - Gilbert A. Nadeau AU - Amnah M. Awan AU - Darcy D. Marciniuk AU - Brandie L. Walker AU - Shawn D. Aaron AU - Denis E. O'Donnell AU - Kenneth R. Chapman AU - François Maltais AU - Paul Hernandez AU - Don D. Sin AU - Andrea Benedetti AU - Jean Bourbeau Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/01/14/23120541.00960-2020.abstract N2 - Rationale Studies assessing dyspnoea and health-related quality of life (HRQoL) in chronic obstructive pulmonary disease (COPD) have focused on patients in clinical settings, not the general population.Objectives Compare the prevalence and severity of dyspnoea and impaired HRQoL in individuals with and without COPD from the general population, focusing on mild-moderate COPD.Methods Analysis of the 3-year Canadian Cohort Obstructive Lung Disease (CanCOLD) study included four subgroups: mild-COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] 1); moderate-COPD (GOLD 2); non-COPD smokers; and non-COPD never-smokers. The primary outcome was dyspnoea (Medical Research Council [MRC] scale), and the secondary outcome was HRQoL (COPD Assessment Test [CAT] score; Saint George's Respiratory Questionnaire [SGRQ] score). Subgroups were analysed by sex, physician-diagnosed COPD status, and exacerbations.Results 1443 participants (mild-COPD [n=397]; moderate-COPD [n=262]; smokers [n=449], and never-smokers [n=335]) were studied. People with mild-COPD were more likely to report more severe dyspnoea (MRC 2 versus 1 [MRC2 versus 1]) than those without COPD (OR [95%CI]: 1.42 [1.05,1.91]), and non-COPD never-smokers (OR [95%CI]: 1.64 [1.07,2.52]). Among people with mild-COPD, more severe dyspnoea was reported in women versus men (MRC2 versus 1; OR [95%CI]: 3.70 [2.23,6.14]); people with, versus without, physician-diagnosed COPD (MRC2 versus 1; OR [95%CI]: 3.27 [1.71,6.23]), and people with, versus without, recent exacerbations (MRC2 versus 1; ≥2 versus 0 exacerbations: OR [95%CI]: 3.62 [1.02,12.86]; MRC≥3 versus 1 [MRC≥3 versuss 1]; 1 versus 0 exacerbation: OR [95%CI]: 9.24 [2.01,42.42]). Similar between-group differences were obtained for CAT and SGRQ scores.Conclusions Careful assessment of dyspnoea and HRQoL could help identify individuals for earlier diagnosis and treatment.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: M. Cherian reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK.Conflict of interest: D. Jensen reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK. He also reports grants and personal fees from AstraZeneca, and grants from Boehringer Ingelheim, Novartis and Tilray, outside the submitted work.Conflict of interest: W. Tan reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK.Conflict of interest: S. Mursleen reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK. S. Mursleen is an employee of and holds shares/options in GSK.Conflict of interest: E.C. Goodall reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK. E.C. Goodall is an employee of GSK.Conflict of interest: G.A. Nadeau reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK. G.A. Nadeau was an employee of and held shares/options in GSK at the time of the analysis.Conflict of interest: A.M. Awan reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK. A.M. Awan is an employee of GlaxoSmithKline.Conflict of interest: D.D. Marciniuk reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK. He also reports consultancy fees and research funding (managed by University of Saskatchewan) from AstraZeneca and Boehringer Ingelheim; consultancy fees from the Canadian Foundation for Healthcare Improvement, and the Chinese Committee of Health and Family Planning; consultancy fees and research funding (managed by University of Saskatchewan) from GSK; consultancy fees from Health Canada; consultancy fees and research funding (managed by University of Saskatchewan) from the Lung Association of Saskatchewan; consultancy fees from Mylan; consultancy fees and research funding (managed by University of Saskatchewan) from Novartis; consultancy fees from the Saskatchewan Ministry of Health, Saskatchewan Health Authority, and Yukon Health and Social Services; research funding (managed by University of Saskatchewan) from Canada Health Infoway, the Canadian Institute of Health Research, the Lung Health Institute of Canada, Sanofi, the Saskatchewan Health Research Foundation and Schering-Plough; and is a spokesperson on behalf of the Canadian Thoracic Society, outside the submitted work.Conflict of interest: B.L. Walker reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK. She also reports advisory board and speaker fees from AstraZeneca and GSK, outside the submitted work.Conflict of interest: S.D. Aaron reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd, and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK.Conflict of interest: D.E. O'Donnell reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd, and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd was funded by GSK.Conflict of interest: K.R. Chapman reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd, and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd. was funded by GSK. He also reports grants from Bayer, grants and personal fees from CSL Behring, grants from Grifols, grants and personal fees from Takeda, grants from Vertex, grants and personal fees from Mereo Biopharma, and grants and personal fees from Sanofi, during the conduct of the study.Conflict of interest: F. Maltais reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd, and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd. was funded by GSK. He also reports research grants paid to his institution from AstraZeneca, GSK and Sanofi, a research grant and fees for speaker bureaus/consultancy from Novartis, grants and personal fees from Boehringer Ingelheim, and a research grant paid to his institution and fees for speaker bureaus/consultancy from Grifols, outside the submitted work.Conflict of interest: P. Hernandez reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd, and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd. was funded by GSK. He also reports honoraria for a medical advisory board from Actelion; honoraria for a medical advisory board and speaker fees for continuing health education, and funding to his institution for conduct of clinical trials from AstraZeneca and Boehringer Ingelheim; funding to his institution for conduct of clinical trials from Cyclomedica; honoraria for medical advisory boards from GlaxoSmithKline and Novartis; funding to his institution for conduct of clinical trials Respivant and Grifols; honoraria for medical advisory boards from Sanofi and Teva; and funding to his institution for conduct of clinical trials from Vertex, all outside the submitted work.Conflict of interest: D.D. Sin reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis. Previous study funding partners were the Respiratory Health Network of the Fonds de la recherche en santé du Québec, the Foundation of the McGill University Health Centre, Almirall, Merck, Nycomed, Pfizer Canada Ltd, and Theratechnologies. Medical writing support provided by Fishawack Communications Ltd. was funded by GSK. He also reports an honorarium for speaking engagement from AstraZeneca and one for attending an advisory board from Boehringer Ingelheim, outside the submitted work.Conflict of interest: A. Benedetti reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis; grants, and lecture and advisory board fees from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd and GlaxoSmithKline Canada Ltd; grants from Canadian Institutes of Health Research and the Respiratory Health Network of the Fonds de la recherche en santé du Québec; medical writing support provided by Fishawack Communications Ltd funded by GSK; grants from Novartis; and grants from Almirall, Merck, Nycomed, Pfizer Canada Ltd, Theratechnologies and The Foundation of the McGill University Health Centre, all during the conduct of the study.Conflict of interest: J. Bourbeau reports the study is currently funded by the Canadian Respiratory Research Network, the Canadian Institutes of Health Research, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd and Novartis; grants, and lecture and advisory board fees from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd and GlaxoSmithKline Canada Ltd; grants from Canadian Institutes of Health Research and the Respiratory Health Network of the Fonds de la recherche en santé du Québec; medical writing support provided by Fishawack Communications Ltd funded by GSK; grants from Novartis; and grants from Almirall, Merck, Nycomed, Pfizer Canada Ltd, Theratechnologies and The Foundation of the McGill University Health Centre, all during the conduct of the study; and consultancy and lecture fees from the Canadian Thoracic Society and CHEST; grants from the Foundation of the MUHC and Aerocrine; grants, and lecture and advisory board fees from Grifols, Novartis and Trudell, and grants from Canadian Institutes of Health Research, all outside the submitted work. ER -